Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Restenosis rates following vertebral artery origin stenting: does stent type make a difference?

Publication ,  Journal Article
Ogilvy, CS; Yang, X; Natarajan, SK; Hauck, EF; Sun, L; Lewis-Mason, L; Hopkins, LN; Siddiqui, AH; Levy, EI
Published in: J Invasive Cardiol
March 2010

OBJECTIVES: To compare our experience with sirolimus and paclitaxel-eluting stents (drug-eluting stents [DES]) and non-drug-eluting stents (NDES) for treatment of vertebral artery (VA) origin stenosis and review the literature. METHODS: A retrospective review of our prospectively collected database was performed. Clinical and radiologic follow up was obtained by reviewing office records and radiology. Data collected included demographics, comorbidities, presenting symptoms, stenosis severity, contralateral VA stenosis and/or carotid stenosis, type of stent used, angioplasty before or after stenting, post-treatment residual stenosis, clinical and radiological follow up and retreatment. Patients with symptomatic > 60% stenosis or asymptomatic > 70% stenosis and/or a hypoplastic or occluded contralateral VA or significant carotid occlusion were chosen for revascularization. RESULTS: Thirty-five patients treated with NDES and 15 treated with DES for management of VA origin stenosis were identified. The technical success rate of the procedure was 100%. There were no procedural complications. There were 7 asymptomatic patients (NDES Group-4, DES Group-3). In the NDES Group, 9 patients had pre-stent angioplasty; 2 had post-stent angioplasty. In the DES group, 4 patients had post-stent angioplasty. Symptoms resolved in 30/31 (96.8%) patients treated with NDES and 11/12 (91.7%) treated with DES. Thirty-six patients had radiologic follow up (median 21.3 months); in-stent restenosis was documented in 11 patients (NDES 9/24 [38%], DES 2/12 [17%]). Among patients receiving NDES, re-stenotic lesions required angioplasty in 7 patients. No patients in the DES group required angioplasty. CONCLUSIONS: DES for treatment of VA origin stenosis may decrease the incidence of restenosis when compared to NDES. Validation in prospective, randomized, multicenter trials is necessary.

Duke Scholars

Published In

J Invasive Cardiol

EISSN

1557-2501

Publication Date

March 2010

Volume

22

Issue

3

Start / End Page

119 / 124

Location

United States

Related Subject Headings

  • Vertebrobasilar Insufficiency
  • Treatment Outcome
  • Stents
  • Sirolimus
  • Secondary Prevention
  • Retrospective Studies
  • Paclitaxel
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ogilvy, C. S., Yang, X., Natarajan, S. K., Hauck, E. F., Sun, L., Lewis-Mason, L., … Levy, E. I. (2010). Restenosis rates following vertebral artery origin stenting: does stent type make a difference? J Invasive Cardiol, 22(3), 119–124.
Ogilvy, Christopher S., Xinyu Yang, Sabareesh K. Natarajan, Erik F. Hauck, Luona Sun, Laura Lewis-Mason, L Nelson Hopkins, Adnan H. Siddiqui, and Elad I. Levy. “Restenosis rates following vertebral artery origin stenting: does stent type make a difference?J Invasive Cardiol 22, no. 3 (March 2010): 119–24.
Ogilvy CS, Yang X, Natarajan SK, Hauck EF, Sun L, Lewis-Mason L, et al. Restenosis rates following vertebral artery origin stenting: does stent type make a difference? J Invasive Cardiol. 2010 Mar;22(3):119–24.
Ogilvy, Christopher S., et al. “Restenosis rates following vertebral artery origin stenting: does stent type make a difference?J Invasive Cardiol, vol. 22, no. 3, Mar. 2010, pp. 119–24.
Ogilvy CS, Yang X, Natarajan SK, Hauck EF, Sun L, Lewis-Mason L, Hopkins LN, Siddiqui AH, Levy EI. Restenosis rates following vertebral artery origin stenting: does stent type make a difference? J Invasive Cardiol. 2010 Mar;22(3):119–124.

Published In

J Invasive Cardiol

EISSN

1557-2501

Publication Date

March 2010

Volume

22

Issue

3

Start / End Page

119 / 124

Location

United States

Related Subject Headings

  • Vertebrobasilar Insufficiency
  • Treatment Outcome
  • Stents
  • Sirolimus
  • Secondary Prevention
  • Retrospective Studies
  • Paclitaxel
  • Middle Aged
  • Male
  • Humans